https://orcid.org/0000-0001-9896-0939
References
- Ruilope LM, Dukat A, Böhm M, et al. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet. 2010;375(9722):1255–1266. doi:10.1016/S0140-6736(09)61966-8
- Kario K, Sun N, Chiang FT, et al. Efficacy and safety of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Asian patients with hypertension: a randomized, double-blind, placebo-controlled study. Hypertension. 2014;63:698–705. doi:10.1161/HYPERTENSIONAHA.113.02002
- McMurray JJV, Packer M, Desai AS, et al; PARADIGM-HF Investigators and Committees. Angiotensin–neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993–1004. doi:10.1056/NEJMoa1409077
- Solomon SD, McMurray JJV, Anand IS, et al; PARAGON-HF Investigators and Committees. Angiotensin–neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med. 2019;381(17):1609–1620. doi:10.1056/NEJMoa1908655
- Schmieder RE, Wagner F, Mayr M, et al. The effect of sacubitril/valsartan compared to olmesartan on cardiovascular remodelling in subjects with essential hypertension: the results of a randomized, double-blind, active-controlled study. Eur Heart J. 2017;38(44):3308–3317. doi:10.1093/eurheartj/ehx525
- Shirai K, Utino J, Otsuka K, et al. A novel blood pressure independent arterial wall stiffness parameter: cardio-ankle vascular index (CAVI). J Atheroscler Thromb. 2006;13(2):101–107. doi:10.5551/jat.13.101
- Lang RM, Bierig M, Devereux RB, et al; Chamber Quantification Writing Group; American Society of Echocardiography’s Guidelines and Standards Committee; European Association of Echocardiography. Recommendations for chamber quantification: a report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005;18(12):1440–1463. doi:10.1016/j.echo.2005.10.005
- Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015;28(1):1–39.e14. doi:10.1016/j.echo.2014.10.003
- Hayashi K, Yamamoto T, Takahara A, et al. Clinical assessment of arterial stiffness with cardio-ankle vascular index: theory and applications. J Hypertens. 2015;33(9):1742–1757. doi:10.1097/HJH.0000000000000651
- Shimizu K, Tabata T, Kiyokawa H, et al. A case demonstrating the cardio-vascular interaction by a new cardio-ankle vascular index during the treatment of concentric hypertrophy. Cardiol Res. 2019;10(1):54–58. doi:10.14740/cr812
- Tabata T, Shimizu K, Morinaga Y, et al. The relationship between cardio- ankle vascular index and left atrial phasic function in hypertensive patients with preserved ejection fraction. Front Med Technol. 2021;3:724089. doi:10.3389/fmedt.2021.724089
- Tabata T, Sato S, Ohno R, et al. Cardio-vascular interaction evaluated by speckle-tracking echocardiography and cardio-ankle vascular index in hypertensive patients. Int J Mol Sci. 2022;23(22):14469. doi:10.3390/ijms232214469
- Zhang C, Ohira M, Iizuka T, et al. Cardio-ankle vascular index relates to left ventricular ejection fraction in patients with heart failure. A retrospective study. Int Heart J. 2013;54(4):216–221. doi:10.1536/ihj.54.216